Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8
Jan 2, 2016Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Jan 2, 2016Cancers (Basel) 2016; 8
Crombag Marie-Rose B S, Jörger Markus, Thürlimann Beat, Schellens Jan H M, Beijnen Jos H, Huitema Alwin D R
Medikamentöse Behandlung des metastasierten Prostatakarzinoms
Cathomas R, Wyler S, Wild P, Thalmann G, Stenner F, Schäfer N, Rentsch C, Müntener M, Jichlinski P, Iselin C, Gillessen Sommer S, Eberli D, Berthold D, Amram M, Aebersold D, Schmid H, Omlin A. Medikamentöse Behandlung des metastasierten Prostatakarzinoms. Schweiz Med Forum 2016; 16:266-72.
Jan 1, 2016Medikamentöse Behandlung des metastasierten Prostatakarzinoms
Jan 1, 2016Schweiz Med Forum 2016; 16:266-72
Cathomas R, Wyler S, Wild P, Thalmann G, Stenner F, Schäfer N, Rentsch C, Müntener M, Jichlinski P, Iselin C, Gillessen Sommer Silke, Eberli D, Berthold D, Amram M-L, Aebersold DM, Schmid Hans-Peter, Omlin Aurelius
Hope and Grace
Renz M. Hope and Grace - Spiritual Experiences in Severe Distress, Illness and Dying. London: Jessica Kingsley Publishers, 2016. ISBN 978-1-78592-030-1.
Jan 1, 2016Hope and Grace
Jan 1, 2016Jessica Kingsley Publishers, ISBN 978-1-78592-030-1
Renz Monika
Hinübergehen
Renz M. Hinübergehen - Was beim Sterben geschieht. Annäherungen an letzte Wahrheiten unseres Lebens. Basel: Herder, 2016. ISBN 978-3-451-06788-4.
Jan 1, 2016Hinübergehen
Jan 1, 2016Herder, ISBN 978-3-451-06788-4
Renz Monika
Der Mystiker aus Nazaret
Renz M. Der Mystiker aus Nazaret - Jesuanische Spiritualität. Basel: Herder, 2016. ISBN 978-3-451-06875-1.
Jan 1, 2016Der Mystiker aus Nazaret
Jan 1, 2016Herder, ISBN 978-3-451-06875-1
Renz Monika
Spirituelle Begleitung im Sterbeprozess
Renz M. Spirituelle Begleitung im Sterbeprozess. Schweizerische Kirchenzeitung 2016; 46/2016
Jan 1, 2016Spirituelle Begleitung im Sterbeprozess
Jan 1, 2016Schweizerische Kirchenzeitung 2016; 46/2016
Renz Monika
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes
Hundsberger T, Weller M, Plasswilm L, Brügge D, Gross M, Pica A, Hermann E, Pesce G, Conen K, Dietrich P, Migliorini D, Roth P, Roelcke U, Hottinger A, Putora P. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol 2016; 126:175-183.
Jan 1, 2016Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes
Jan 1, 2016J Neurooncol 2016; 126:175-183
Hundsberger Thomas, Weller M, Plasswilm Ludwig, Brügge Detlef, Gross M W, Pica A, Hermann E, Pesce G, Conen K, Dietrich P Y, Migliorini D, Roth P, Roelcke U, Hottinger A F, Putora Paul Martin
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
Jan 1, 2016Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Jan 1, 2016J Immunother 2016; 39:379-382
Diem Stefan, Goldinger Simone M, Urner-Bloch Ursula, Siano Marco, Dummer Reinhard, Speiser Daniel E, Maillard Samia A, Rüesch Reinhard, Keller Fabienne, Flatz Lukas
Chronic inflammatory demyelinating polyneuropathy- still a challenging diagnosis
Leupold D, Schilg-Hafer L, Felbecker A, Zieglgänsberger D, Tettenborn B, Hundsberger T (2016). Chronic inflammatory demyelinating polyneuropathy- still a challenging diagnosis.
Dec 30, 2015Chronic inflammatory demyelinating polyneuropathy- still a challenging diagnosis
Dec 30, 2015Jahrestagung 2015 Schweizerische Neurologische Gesellschaft
Leupold Daniela, Schilg-Hafer Lenka, Felbecker Ansgar, Zieglgänsberger Dominik, Tettenborn Barbara, Hundsberger Thomas
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2015; 34:495-500.
Dec 28, 2015Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Dec 28, 2015J Clin Oncol 2015; 34:495-500
Taverna Christian, Zucca Emanuele, Heijnen Ingmar A F M, Rusterholz Corinne, Rondeau Stephanie, Biaggi Rudolf Christine, Lohri Andreas, Vorobiof Daniel A, Rauch Daniel, Raats Johann, Laszlo Daniele, Vanazzi Anna, Del Giglio Auro, Cevreska Lidija, Pabst Thomas, Mingrone Walter, Hitz Felicitas, Martinelli Giovanni, Ghielmini Michele
For choosing axillary treatment, and adjuvant hormonal treatment
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary treatment, and adjuvant hormonal treatment. Breast Cancer 2015
Dec 21, 2015For choosing axillary treatment, and adjuvant hormonal treatment
Dec 21, 2015Breast Cancer 2015
Toi Masakazu, Ohno Shinji, Saeki Toshiaki, Nakamura Seigo, Thürlimann Beat
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Hadji P, Gnant M, Gray R, Harbeck N, Thürlimann B, Untch M, Cortes J, Martin M, Albert U, Conte P, Ejlertsen B, Bergh J, Kaufmann M, Smith I, Dodwell D, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, Costa L, Body J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Ann Oncol 2015
Dec 17, 2015Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Dec 17, 2015Ann Oncol 2015
Hadji P, Gnant M, Gray R, Harbeck N, Thürlimann Beat, Untch M, Cortes J, Martin M, Albert U-S, Conte P-F, Ejlertsen B, Bergh J, Kaufmann M, Smith I, Dodwell D, Coleman R E, Wilson C, Powles T J, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Holen I
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, von Minckwitz G, Untch M, Paepke S, Loibl S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer J, Lederer B, Schneeweiss A. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2015; 53:65-74.
Dec 13, 2015Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Dec 13, 2015Eur J Cancer 2015; 53:65-74
Marme Frederik, von Minckwitz Gunter, Untch Michael, Paepke Stefan, Loibl Sibylle, Kümmel Sherko, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens-Uwe, Lederer Bianca, Schneeweiss Andreas
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
Dec 11, 2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Dec 11, 2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982-2011
Feller A, Clough-Gorr K, Arndt V, Steiner A, Mousavi M, Frick H, Bouchardy C, Bordoni A, Fehr M, The Nicer Working Group. Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982-2011. Swiss Med Wkly 2015; 145:w14245.
Dec 10, 2015Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982-2011
Dec 10, 2015Swiss Med Wkly 2015; 145:w14245
Feller Anita, Clough-Gorr Kerri M, Arndt Volker, Steiner Annik, Mousavi Mohsen, Frick Harald, Bouchardy Christine, Bordoni Andrea, Fehr Martin, The Nicer Working Group
Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis
Gueller U, Tarantino I, Cerny T, Ulrich A, Schmied B, Warschkow R. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer 2015
Dec 9, 2015Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis
Dec 9, 2015Gastric Cancer 2015
Gueller Ulrich, Tarantino Ignazio, Cerny Thomas, Ulrich Alexis, Schmied Bruno, Warschkow Rene
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer
Rothermundt C, Hader C, Gillessen Sommer S. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol 2015
Nov 29, 2015Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer
Nov 29, 2015Ann Oncol 2015
Rothermundt Christian, Hader C, Gillessen Sommer Silke
Circulating DNA and survival in solid tumors
Ocana A, Pandiella A, Andrés-Pretel F, Seruga B, Corrales-Sanchez V, Serrano-Heras G, Gascon-Escribano M, Vera-Badillo F, Templeton A, Garcia-Olmo D, Diez-Gonzalez L, Amir E. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev 2015
Nov 24, 2015Circulating DNA and survival in solid tumors
Nov 24, 2015Cancer Epidemiol Biomarkers Prev 2015
Ocana Alberto, Pandiella Atanasio, Andrés-Pretel Fernando, Seruga Bostjan, Corrales-Sanchez Verónica, Serrano-Heras Gemma, Gascon-Escribano Maria José, Vera-Badillo Francisco, Templeton Arnoud, Garcia-Olmo Dolores C, Diez-Gonzalez Laura, Amir Eitan
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.
Nov 23, 2015Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Nov 23, 2015Ann Oncol 2015; 27:281-6
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh Martin, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H, Scherber R, Kosiorek H, Dueck A, Kiladjian J, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes A, Hernández-Maraver D, Döhner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Maldonado N, Barosi G, Ferrari M, Gale R, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst P, Commandeur S, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi A, Passamonti F, Samuelsson J, Mesa R. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol 2015; 34:151-9.
Nov 23, 2015Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Nov 23, 2015J Clin Oncol 2015; 34:151-9
Geyer Holly L, Scherber Robyn, Kosiorek Heidi, Dueck Amylou C, Kiladjian Jean-Jacques, Xiao Zhijian, Slot Stefanie, Zweegman Sonja, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Döhner Konstanze, Harrison Claire N, Radia Deepti, Muxi Pablo, Besses Carlos, Cervantes Francisco, Johansson Peter L, Andreasson Bjorn, Rambaldi Alessandro, Barbui Tiziano, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Maldonado Norman, Barosi Giovanni, Ferrari Maria L, Gale Robert Peter, Birgegard Gunnar, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Zhang Peihong, te Boekhorst Peter A W, Commandeur Suzan, Schouten Harry, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Lehmann Thomas, Senyak Zhenya, Vannucchi Alessandro M, Passamonti Francesco, Samuelsson Jan, Mesa Ruben A